Related Experiment Video
Updated: Mar 20, 2026
Inducement and Evaluation of a Murine Model of Experimental Myopia
Published on: January 22, 2019
Real-world evidence for atropine titration in myopia control: a comparative study of three low-dose regimens in
Hui-Xia Li1, Peng Wu1, Wen-Ping Qi2
1Department of refractive surgery, Inner Mongolia Chaoju Eye Hospital, Hohhot, China.
Insights
Low-concentration atropine eye drops effectively slow myopia progression in children. The 0.025% concentration showed optimal efficacy and tolerability for managing pediatric myopia.
Area of Science:
- Ophthalmology
- Pediatric Medicine
- Pharmacology
Background:
- Myopia, or nearsightedness, is a growing public health concern in children.
- Effective interventions are needed to slow myopia progression and prevent associated visual impairments.
Purpose of the Study:
- To compare the efficacy of 0.01%, 0.025%, and 0.05% atropine eye drops in slowing myopia progression in Chinese children aged 6-18 years.
- To assess changes in spherical equivalent (SE) and axial length (AL) as primary outcomes.
Main Methods:
- A prospective, multi-center study involving 175 myopic children in China.
- Nightly instillation of varying low-concentration atropine eye drops (0.01%, 0.025%, 0.05%) for 12 months.
- Statistical analysis using repeated-measures ANOVA and regression models to evaluate SE and AL changes.
Main Results:
- All atropine concentrations reduced myopia progression. The 0.05% group had the lowest SE progression (-0.27 D), followed by 0.025% (-0.35 D) and 0.01% (-0.44 D).
- Axial length elongation was numerically lowest in the 0.025% group (0.21 mm), though not statistically significant across groups.
- Regression analysis indicated axial length change explained more SE variation in the 0.025% and 0.05% groups compared to the 0.01% group.
Conclusions:
- Low-concentration atropine eye drops are effective for myopia control in children.
- 0.025% atropine demonstrates a favorable balance of efficacy and tolerability, comparable to 0.05% for axial elongation control with potentially fewer side effects.
- 0.025% atropine is recommended as a first-line pharmacologic treatment for pediatric myopia management.
Purpose:
To evaluate and compare the efficacy of 0.01%, 0.025%, and 0.05% atropine eye drops in slowing myopia progression among Chinese children aged 6-18 years, focusing on changes in spherical equivalent (SE) and axial length (AL).
Methods:
In this prospective, real world based, multi-center study, 175 children with myopia were followed for 12 months at three tertiary ophthalmic hospitals in China. Participants received nightly instillations of 0.01%, 0.025%, or 0.05% atropine in affected eyes. Primary outcomes included changes in SE and AL. Secondary outcomes involved corneal curvature, intraocular pressure, and biometric parameters. Statistical analyses included repeated-measures ANOVA, linear regression, and seemingly unrelated regression models.
Results:
All three concentrations demonstrated effectiveness in reducing myopia progression. At 12 months, SE progression was lowest in the 0.05% group (-0.27 ± 0.72 D), followed by 0.025% (-0.35 ± 0.59 D) and 0.01% (-0.44 ± 1.02 D), with a significant difference between 0.05% and 0.01% (P = 0.014). AL elongation was numerically lowest in the 0.025% group (0.21 ± 0.19 mm), while differences among groups were not statistically significant (P = 0.299). Regression analysis showed that AL change explained over 34% of SE variation in the 0.025% and 0.05% groups, compared to 14% in the 0.01% group.
Conclusion:
Low-concentration atropine is effective in controlling myopia progression in children. Among the three concentrations, 0.025% atropine offers better efficacy and tolerability, providing comparable axial elongation control to 0.05% with potentially fewer side effects. These findings support its use as a first-line pharmacologic option for pediatric myopia management in clinical practice.
More Related Videos
06:19Comparison of Three Clinical Stereoscopic Methods for Measuring Binocular Visual Function During Amblyopic Treatment in Unilateral Amblyopia
Published on: September 27, 2024
08:30Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
01:23Ophthalmic Drug Delivery Systems
01:28Angle Closure Glaucoma: Treatment
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions